{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:24:56Z","timestamp":1772475896897,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"DOI":"10.1007\/s13365-025-01291-6","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:46:41Z","timestamp":1772473601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MicroRNA biomarkers for JC virus reactivation and progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients: a systematic review"],"prefix":"10.1007","author":[{"given":"Hasan","family":"Kaveyee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javad","family":"Aalipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Etemadifar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Roozbeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadmahdi","family":"Emami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pantea","family":"Miralaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"3","key":"1291_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/1352458520917925","volume":"27","author":"H Butzkueven","year":"2021","unstructured":"Butzkueven H, Trojano M, Kappos L, Spelman T, Wiendl H, Rosales K et al (2021) Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<Superscript>\u00ae<\/Superscript> observational program (TOP). Mult Scler J 27(3):410\u20139","journal-title":"Mult Scler J"},{"key":"1291_CR2","doi-asserted-by":"crossref","unstructured":"Chappell M, Sanderson A, Arun T, Green C, Davies H, Tempest M et al (2024 Sept) Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the \u2018suboptimal therapy\u2019 patient population. J Neurol Sci 464:123172","DOI":"10.1016\/j.jns.2024.123172"},{"key":"1291_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.msard.2016.11.002","volume":"11","author":"T Saida","year":"2017","unstructured":"Saida T, Kira Jichi, Kishida S, Yamamura T, Sudo Y, Ogiwara K et al (2017) Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: a double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord 11:25\u201331","journal-title":"Mult Scler Relat Disord"},{"key":"1291_CR4","doi-asserted-by":"crossref","unstructured":"Vivekanandan G, Abubacker AP, Myneni R, Chawla HV, Iqbal A, Grewal A et al (2021) Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review. Cureus [Internet]. Apr 30 [cited 2025 Aug 25]; Available from: https:\/\/www.cureus.com\/articles\/55429-risk-of-progressive-multifocal-leukoencephalopathy-in-multiple-sclerosis-patient-treated-with-natalizumab-a-systematic-review","DOI":"10.7759\/cureus.14764"},{"key":"1291_CR5","doi-asserted-by":"publisher","unstructured":"Blankenbach K, Schwab N, Hofner B, Adams O, Keller-Stanislawski B, Warnke C Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. Neurology [Internet]. 2019 May 7 [cited 2025 Aug 25];92(19). Available from: https:\/\/www.neurology.org\/doi\/https:\/\/doi.org\/10.1212\/WNL.0000000000007451","DOI":"10.1212\/WNL.0000000000007451"},{"issue":"15","key":"1291_CR6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ et al (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80(15):1430\u20131438","journal-title":"Neurology"},{"issue":"16","key":"1291_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1212\/WNL.0000000000207622","volume":"101","author":"F Schweitzer","year":"2023","unstructured":"Schweitzer F, Laurent S, Cortese I, Fink GR, Silling S, Skripuletz T et al (2023) Progressive multifocal leukoencephalopathy: pathogenesis, diagnostic tools, and potential biomarkers of response to therapy. Neurology 101(16):700\u2013713","journal-title":"Neurology"},{"key":"1291_CR8","doi-asserted-by":"crossref","unstructured":"Wattjes MP, Vennegoor A, Steenwijk MD, De Vos M, Killestein J, Van Oosten BW et al (2015 July) MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry 86(7):793\u2013798","DOI":"10.1136\/jnnp-2014-308630"},{"key":"1291_CR9","doi-asserted-by":"crossref","unstructured":"Ambros V (2004 Sept) The functions of animal MicroRNAs. Nature 431(7006):350\u2013355","DOI":"10.1038\/nature02871"},{"key":"1291_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O\u2019Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 9:402","journal-title":"Front Endocrinol"},{"key":"1291_CR11","doi-asserted-by":"crossref","unstructured":"He L, Hannon GJ MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004 July 1;5(7):522\u201331","DOI":"10.1038\/nrg1379"},{"issue":"12","key":"1291_CR12","doi-asserted-by":"publisher","first-page":"e1003018","DOI":"10.1371\/journal.ppat.1003018","volume":"8","author":"RP Kincaid","year":"2012","unstructured":"Kincaid RP, Sullivan CS (2012) Virus-Encoded micrornas: an overview and a look to the Future. Hobman TC. Editor PLoS Pathog 8(12):e1003018","journal-title":"Editor PLoS Pathog"},{"issue":"1","key":"1291_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.virol.2009.02.017","volume":"387","author":"CS Sullivan","year":"2009","unstructured":"Sullivan CS, Sung CK, Pack CD, Grundhoff A, Lukacher AE, Benjamin TL et al (2009) Murine polyomavirus encodes a MicroRNA that cleaves early RNA transcripts but is not essential for experimental infection. Virology 387(1):157\u2013167","journal-title":"Virology"},{"key":"1291_CR14","doi-asserted-by":"publisher","first-page":"1441733","DOI":"10.3389\/fimmu.2024.1441733","volume":"15","author":"A Zabalza","year":"2024","unstructured":"Zabalza A, Pappolla A, Comabella M, Montalban X, Malhotra S (2024) MiRNA-based therapeutic potential in multiple sclerosis. Front Immunol 15:1441733","journal-title":"Front Immunol"},{"issue":"1","key":"1291_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10(1):89","journal-title":"Syst Rev"},{"issue":"5","key":"1291_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000510849","volume":"83","author":"K Kapica-Topczewska","year":"2020","unstructured":"Kapica-Topczewska K, Collin F, Tarasiuk J, Czarnowska A, Chor\u0105\u017cy M, Miro\u0144czuk A et al (2020) John Cunningham virus status, seroconversion rate, and the risk of progressive multifocal leukoencephalopathy in Polish John Cunningham virus-seronegative patients with relapsing-remitting multiple sclerosis. Eur Neurol 83(5):487\u2013492","journal-title":"Eur Neurol"},{"issue":"1","key":"1291_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1743-422X-11-158","volume":"11","author":"O Lagatie","year":"2014","unstructured":"Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ (2014) Viral miRNAs in plasma and urine divulge JC polyomavirus infection. Virol J 11(1):158","journal-title":"Virol J"},{"issue":"6","key":"1291_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s13365-015-0325-3","volume":"21","author":"I Giovannelli","year":"2015","unstructured":"Giovannelli I, Martelli F, Repice A, Massacesi L, Azzi A, Giannecchini S (2015) Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy. J Neurovirol 21(6):666\u2013670","journal-title":"J Neurovirol"},{"issue":"5","key":"1291_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13365-017-0560-x","volume":"23","author":"P Basnyat","year":"2017","unstructured":"Basnyat P, Virtanen E, Elovaara I, Hagman S, Auvinen E (2017) JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients. J Neurovirol 23(5):734\u2013741","journal-title":"J Neurovirol"},{"issue":"3","key":"1291_CR20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/v13030468","volume":"13","author":"S Agostini","year":"2021","unstructured":"Agostini S, Mancuso R, Costa AS, Caputo D, Clerici M (2021) JCPyV miR-J1-5p in urine of Natalizumab-Treated multiple sclerosis patients. Viruses 13(3):468","journal-title":"Viruses"},{"issue":"2","key":"1291_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/jcm11020347","volume":"11","author":"C Prezioso","year":"2022","unstructured":"Prezioso C, Ciotti M, Brazzini G, Piacentini F, Passerini S, Grimaldi A et al (2022) Diagnostic value of JC polyomavirus Viruria, Viremia, serostatus and MicroRNA expression in multiple sclerosis patients undergoing immunosuppressive treatment. J Clin Med 11(2):347","journal-title":"J Clin Med"},{"issue":"12","key":"1291_CR22","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1099\/vir.0.023184-0","volume":"91","author":"LJ Marshall","year":"2010","unstructured":"Marshall LJ, Dunham L, Major EO (2010) Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter\/enhancer of JC virus and supports viral activity. J Gen Virol 91(12):3042\u20133052","journal-title":"J Gen Virol"},{"key":"1291_CR23","doi-asserted-by":"crossref","unstructured":"Meira M, Sievers C, Hoffmann F, Derfuss T, Kuhle J, Kappos L et al (2014 Sept) MiR-126: a novel route for natalizumab action? Mult Scler J 20(10):1363\u20131370","DOI":"10.1177\/1352458514524998"},{"key":"1291_CR24","doi-asserted-by":"crossref","unstructured":"Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, D\u00e9card BF et al (2016 June) Natalizumab-induced POU2AF1\/Spi-B upregulation: A possible route for PML development. Neurol Neuroimmunol Neuroinflammation 3(3):e223","DOI":"10.1212\/NXI.0000000000000223"},{"key":"1291_CR25","doi-asserted-by":"publisher","first-page":"819911","DOI":"10.3389\/fneur.2022.819911","volume":"13","author":"R Mancuso","year":"2022","unstructured":"Mancuso R, Agostini S, Hernis A, Caputo D, Galimberti D, Scarpini E et al (2022) Alterations of the miR-126-3p\/POU2AF1\/Spi-B axis and JCPyV reactivation in multiple sclerosis patients receiving natalizumab. Front Neurol 13:819911","journal-title":"Front Neurol"},{"issue":"14","key":"1291_CR26","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1177\/1352458514534513","volume":"20","author":"M Mu\u00f1oz-Culla","year":"2014","unstructured":"Mu\u00f1oz-Culla M, Irizar H, Castillo-Trivi\u00f1o T, S\u00e1enz-Cuesta M, Sep\u00falveda L, Lopetegi I et al (2014) Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler J 20(14):1851\u20139","journal-title":"Mult Scler J"},{"issue":"12","key":"1291_CR27","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.3390\/v16121950","volume":"16","author":"K Takahashi","year":"2024","unstructured":"Takahashi K, Nakamichi K, Sato Y, Katano H, Hasegawa H, Saijo M et al (2024) Performance of ultrasensitive polymerase chain reaction testing for JC polyomavirus in cerebrospinal fluid compared with pathological diagnosis of progressive multifocal leukoencephalopathy. Viruses 16(12):1950","journal-title":"Viruses"},{"key":"1291_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3389\/fonc.2019.00711","volume":"9","author":"L Del Valle","year":"2019","unstructured":"Del Valle L, Pi\u00f1a-Oviedo S (2019) Human polyomavirus JCPyV and its role in progressive multifocal leukoencephalopathy and oncogenesis. Front Oncol 9:711","journal-title":"Front Oncol"},{"key":"1291_CR29","doi-asserted-by":"crossref","unstructured":"Ferretti F, Bestetti A, Yiannoutsos CT, Musick BS, Gerevini S, Passeri L et al Diagnostic and prognostic value of JC virus DNA in plasma in progressive multifocal leukoencephalopathy. Clin Infect Dis 2018 June 18;67(1):65\u201372","DOI":"10.1093\/cid\/ciy030"},{"issue":"5","key":"1291_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/diseases12050100","volume":"12","author":"DS Mouliou","year":"2024","unstructured":"Mouliou DS (2024) John Cunningham virus and progressive multifocal leukoencephalopathy: a falsely played diagnosis. Diseases 12(5):100","journal-title":"Diseases"},{"key":"1291_CR31","doi-asserted-by":"crossref","unstructured":"Hegen H, Auer M, Bsteh G, Di Pauli F, Plavina T, Walde J et al (2017) Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. Ruprecht K, editor. PLOS ONE. ;12(3):e0174005","DOI":"10.1371\/journal.pone.0174005"},{"issue":"4","key":"1291_CR32","doi-asserted-by":"publisher","first-page":"e1008523","DOI":"10.1371\/journal.ppat.1008523","volume":"16","author":"K Takahashi","year":"2020","unstructured":"Takahashi K, Sato Y, Sekizuka T, Kuroda M, Suzuki T, Hasegawa H et al (2020) L <>Del Valle editor High expression of JC polyomavirus-encoded MicroRNAs in progressive multifocal leukoencephalopathy tissues and its repressive role in virus replication. PLOS Pathog 16 4 e1008523","journal-title":"PLOS Pathog"},{"key":"1291_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jcv.2018.02.007","volume":"102","author":"E Virtanen","year":"2018","unstructured":"Virtanen E, Sepp\u00e4l\u00e4 H, Helanter\u00e4 I, Laine P, Lautenschlager I, Paulin L et al (2018) BK polyomavirus microRNA expression and sequence variation in polyomavirus-associated nephropathy. J Clin Virol 102:70\u20136","journal-title":"J Clin Virol"},{"issue":"3","key":"1291_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1927","volume":"27","author":"F Martelli","year":"2017","unstructured":"Martelli F, Giannecchini S (2017) Polyomavirus microRNAs circulating in biological fluids during viral persistence. Rev Med Virol 27(3):e1927","journal-title":"Rev Med Virol"},{"key":"1291_CR35","doi-asserted-by":"crossref","unstructured":"Marshall LJ, Ferenczy MW, Daley EL, Jensen PN, Ryschkewitsch CF, Major EO (2014) Lymphocyte Gene Expression and JC Virus Noncoding Control Region Sequences Are Linked with the Risk of Progressive Multifocal Leukoencephalopathy. Longnecker RM, editor. J Virol. ;88(9):5177\u201383","DOI":"10.1128\/JVI.03221-13"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-025-01291-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-025-01291-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-025-01291-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:46:44Z","timestamp":1772473604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-025-01291-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":35,"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1007\/s13365-025-01291-6","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}